The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
 
Manish A. Shah
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Oncolys BioPharma (Inst)
 
Jong-Mu Sun
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Peter C. Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Eisai; IDEAYA Biosciences; Legend Biotech; Legend Biotech; Lilly; loxo; Loxo; Merck; Novartis; Ono Pharmaceutical; Sanofi; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
Antoine Adenis
Honoraria - BMS; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Bayer Health; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre
Research Funding - Arcus Ventures (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pierre Fabre; SERVIER
 
Toshihiko Doi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Gilead Sciences; Kaken Pharmaceutical; Kyowa Hakko Kirin; NanoCarrier; Noil-Immune Biotech; Noil-Immune Biotech; Oncolys BioPharma; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Pharma; Takeda
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); RIN Institute (Inst); SHIONOGI (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; BMS; Merck; MSD
Research Funding - Astellas Amgen BioPharama (Inst); BMS (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Zhigang Li
No Relationships to Disclose
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Wasat Mansoor
Honoraria - Bristol-Myers Squibb; Servier
Consulting or Advisory Role - Bristol-Myers Squibb; Servier
Speakers' Bureau - Bristol-Myers Squibb; Servier
 
Shau-Hsuan Li
No Relationships to Disclose
 
Patrapim Sunpaweravong
Honoraria - Amgen; AstraZeneca; Baxter; Bayer; BMS; DKSH; Eisai; Ipsen; Juniper Biologics; MSD; Novartis; Pfizer; Roche; Taiho Pharmaceutical; ZP Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Eisai; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; Boehringer Ingelheim; Eisai; MSD; Novartis; Pfizer; Roche; Taiho Pharmaceutical
 
Maria Alsina Maqueda
Honoraria - Amgen; Bristol-Myers Squibb; Lilly; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD
 
Gary L Buchschacher
Research Funding - AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Jimin Wu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sukrut Shah
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Pooja Bhagia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jean-Philippe Metges
Honoraria - Bayer; Bristol-Myers Squibb; MSD